Compare Meta Platforms Inc (META) vs Summit Therapeutics Inc (SMMT) Price & Performance

META stock trades at $646.01, down 2.79% over 24 hours, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $10.44 surpassing expectations of $6.70. Revenue grew to $201.0B in 2025, though net income dipped to $60.5B. Analyst sentiment remains overwhelmingly positive, with a consensus price target of $807.17. Recent news highlights the launch of Muse Spark AI and a legal ruling in Massachusetts regarding youth addiction claims.

The outlook for META is favorable, driven by AI innovation and robust financials, but risks include regulatory lawsuits and high capital expenditures. With 79% of analysts rating it a buy and a price target implying 25% upside, the stock presents a growth opportunity, though investors should weigh legal and competitive pressures against its strong market position and profitability.

Summit Therapeutics (SMMT) trades at $13.50, down 2.24% on the day, reflecting ongoing volatility. The company reported a net loss of $1.08 billion for 2025, with negative ROE and ROA, but recent news includes the $105 million divestiture of ridinilazole to sharpen its oncology focus. Technical indicators are bearish, though RSI suggests potential oversold conditions. Analyst consensus remains optimistic with a $15.57 price target and 66.7% buy ratings.

The outlook hinges on clinical success of its lead oncology candidate, ivonescimab, which showed promising survival data. Key risks include high cash burn, binary drug trial outcomes, and shareholder litigation. The stock offers high-risk, high-reward potential for investors betting on pipeline success, but requires careful risk management due to financial losses and volatility.